Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Scoring model with serum albumin and CA19-9 for metastatic pancreatic cancer in second-line treatment: results from the NAPOLEON study.
Komori A, Otsu S, Shimokawa M, Otsuka T, Koga F, Ueda Y, Nakazawa J, Arima S, Fukahori M, Okabe Y, Makiyama A, Taguchi H, Honda T, Shibuki T, Nio K, Ide Y, Ureshino N, Mizuta T, Shirakawa T, Mitsugi K. Komori A, et al. Among authors: shibuki t. Int J Clin Oncol. 2023 Aug;28(8):1073-1081. doi: 10.1007/s10147-023-02354-6. Epub 2023 May 20. Int J Clin Oncol. 2023. PMID: 37209158
Acute Prevertebral Calcific Tendinitis.
Shibuki T, Goto H, Fukushima K, Mizuta T. Shibuki T, et al. Intern Med. 2017;56(10):1275. doi: 10.2169/internalmedicine.56.8197. Epub 2017 May 15. Intern Med. 2017. PMID: 28502954 Free PMC article. No abstract available.
Diffuse Esophageal Spasm.
Shibuki T, Kawakubo H, Kawachi K, Mizuta T. Shibuki T, et al. Intern Med. 2017;56(11):1447. doi: 10.2169/internalmedicine.56.8240. Epub 2017 Jun 1. Intern Med. 2017. PMID: 28566615 Free PMC article. No abstract available.
Retracted: Seropositivity and Titers of Anti-Smooth Muscle Actin Antibody Are Associated with Relapse of Type 1 Autoimmune Hepatitis.
Otsuka T, Isoda H, Araki N, Kubotsu Y, Kawaguchi Y, Nakashita S, Yoshioka W, Kawazoe S, Kawasoe H, Ide Y, Mizuta T; Saga Study Group of Liver Diseases (SASLD); Shibuki T. Otsuka T, et al. Among authors: shibuki t. Med Sci Monit. 2018 Mar 26;24:1768. doi: 10.12659/MSM.910003. Med Sci Monit. 2018. PMID: 29581415 Free PMC article. No abstract available.
A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study.
Otsuka T, Shirakawa T, Shimokawa M, Koga F, Kawaguchi Y, Ueda Y, Nakazawa J, Komori A, Otsu S, Arima S, Fukahori M, Okabe Y, Makiyama A, Taguchi H, Honda T, Shibuki T, Nio K, Ide Y, Mizuta T, Mitsugi K, Ureshino N. Otsuka T, et al. Among authors: shibuki t. Int J Clin Oncol. 2021 May;26(5):941-950. doi: 10.1007/s10147-021-01859-2. Epub 2021 Jan 23. Int J Clin Oncol. 2021. PMID: 33483857
Correction to: A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study.
Otsuka T, Shirakawa T, Shimokawa M, Koga F, Kawaguchi Y, Ueda Y, Nakazawa J, Komori A, Otsu S, Arima S, Fukahori M, Okabe Y, Makiyama A, Taguchi H, Honda T, Shibuki T, Nio K, Ide Y, Mizuta T, Mitsugi K, Ureshino N. Otsuka T, et al. Among authors: shibuki t. Int J Clin Oncol. 2021 May;26(5):951-953. doi: 10.1007/s10147-021-01880-5. Int J Clin Oncol. 2021. PMID: 33656656 No abstract available.
Gemcitabine plus nab-paclitaxel in older patients with metastatic pancreatic cancer: A post-hoc analysis of the real-world data of a multicenter study (the NAPOLEON study).
Koga F, Kawaguchi Y, Shimokawa M, Murayama K, Nakashita S, Oza N, Ureshino N, Takahashi H, Ueda Y, Nakazawa J, Komori A, Otsu S, Arima S, Fukahori M, Makiyama A, Taguchi H, Honda T, Shibuki T, Nio K, Ide Y, Mizuta T, Shirakawa T, Otsuka T, Mitsugi K. Koga F, et al. Among authors: shibuki t. J Geriatr Oncol. 2022 Jan;13(1):82-87. doi: 10.1016/j.jgo.2021.06.011. Epub 2021 Jun 29. J Geriatr Oncol. 2022. PMID: 34215525
Gemcitabine Plus Nanoparticle Albumin-bound Paclitaxel Versus FOLFIRINOX for Recurrent Pancreatic Cancer After Resection.
Taguchi H, Otsuka T, Shimokawa M, Arima S, Hashimoto S, Ido A, Koga F, Ueda Y, Nakazawa J, Komori A, Otsu S, Fukahori M, Makiyama A, Honda T, Shibuki T, Mizuta T, Mitsugi K, Nio K, Ide Y, Ureshino N, Shirakawa T. Taguchi H, et al. Among authors: shibuki t. Anticancer Res. 2021 Jul;41(7):3573-3582. doi: 10.21873/anticanres.15145. Anticancer Res. 2021. PMID: 34230153
Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer: A Multicenter Observational Study (NAPOLEON Study).
Arima S, Kawahira M, Shimokawa M, Ido A, Koga F, Ueda Y, Nakazawa J, Komori A, Otsu S, Fukahori M, Makiyama A, Taguchi H, Honda T, Shibuki T, Mitsugi K, Nio K, Ide Y, Ureshino N, Mizuta T, Shirakawa T, Otsuka T. Arima S, et al. Among authors: shibuki t. Pancreas. 2021 Aug 1;50(7):957-964. doi: 10.1097/MPA.0000000000001859. Pancreas. 2021. PMID: 34347735
36 results